Table 1.
Baseline characteristics of participants
| Tamponade+misoprostol (n=57) | Misoprostol alone (n=59) | |||
| Median (IQR) age (years) | 27 | (22–33) | 27 | (24–32) |
| Multiparous | 40/57 | (70) | 40/59 | (68) |
| Multiple pregnancy | 6/57 | (10) | 4/59 | (7) |
| Labour induced | 7/57 | (12) | 7/59 | (12) |
| Labour augmented | 14/57 | (25) | 17/59 | (29) |
| Spontaneous vaginal birth | 57/57 | (100) | 59/59 | (100) |
| Place of delivery | ||||
| Primary healthcare facility | 11/57 | (19) | 12/59 | (20) |
| District hospital | 9/57 | (16) | 9/59 | (15) |
| Tertiary/teaching hospital | 37/57 | (65) | 38/59 | (64) |
| Median (IQR) birth weight of neonate (g) | 3100 | (2633–3500) | 3000 | (2725–3200) |
| Abruptio placentae | 3/57 | (5) | 2/59 | (3) |
| Intrauterine death | 8/57 | (14) | 6/59 | (10) |
| Preventive oxytocin | 52/57 | (91) | 55/59 | (93) |
| PPH diagnosis within 120 min of birth | 44/57 | (77) | 44/59 | (75) |
| Qualified staff* available within 15 min of PPH diagnosis | 49/57 | (86) | 53/59 | (90) |
| Estimated blood loss≥1000 mL | ||||
| At PPH diagnosis time | 8/57 | (14) | 8/59 | (14) |
| At randomisation time | 23/55 | (42) | 15/58 | (26) |
| Oxytocin use for PPH treatment | 57/57 | (100) | 57/59 | (97) |
| Oxytocin within 10 min of diagnosis | 43/57 | (75) | 45/57 | (79) |
| Median (IQR) dose of oxytocin (UI) | 30 | (20–40) | 30 | (20–40) |
Values are number with characteristic/number in group (percentage) unless stated otherwise.
*At least one doctor and one midwife.
PPH, postpartum haemorrhage; IU, international unit.